Evaluates safety and efficacy of bezisterim for early Parkinson's disease, suggesting effectiveness for patients.
This report captures the baseline characteristics of participants in SUNRISE-PD, which is designed to evaluate the safety and efficacy of bezisterim for the treatment of motor and non-motor symptoms of early Parkinson’s disease (PD).
No takes yet. Share an insight, caveat, or question.
Palumbo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: